Scientific R&D

Respiratory diseases are common and widespread conditions that primarily affect the trachea, bronchi, lungs, and thoracic cavity. In mild cases, symptoms often include coughing, chest pain, and difficulty breathing, while more severe cases can lead to shortness of breath, hypoxia, and even fatal respiratory failure. These diseases are the third leading cause of death in urban areas and the leading cause in rural regions. Factors such as air pollution, smoking, an aging population, and others have contributed to persistently high and rising rates of morbidity and mortality worldwide from chronic bronchitis, emphysema, cor pulmonale, bronchial asthma, lung cancer, diffuse interstitial pulmonary fibrosis, and pulmonary infections. In China, over 300 million people suffer from chronic respiratory diseases, including nearly 99.9 million with chronic obstructive pulmonary disease (COPD).Respiratory diseases pose a significant threat to public health, imposing heavy burdens on individuals, families, and society at large – creating an urgent need for more effective treatment options. 

To address the limitations of conventional therapies – such as steroid dependence and severe side effects – SBK leverages its AI-driven metabolic research platform and deep R&D expertise to actively expand its respiratory disease pipeline. The current portfolio includes investigational Chemical Class 1 New Drugs such as SBK-001, which specifically target key challenges in respiratory disease treatment through a differentiated strategy that overcomes traditional therapeutic constraints. Featuring uniquely designed chemical structures, these novel candidates exhibit innovative mechanisms of action, optimized pharmacokinetic profiles, and enhanced efficacy – potentially delivering safer and more effective treatment options for respiratory disease patients. By addressing critical unmet clinical needs, we aim to redefine therapeutic standards and bring new momentum to improving patient outcomes.